Search

The present study aimed to determine whether the expression of microRNA (miR)-10b was correlated with the molecular subtypes of early invasive ductal carcinoma of the breast. In situ hybridization was used to detect the expression of miR‑10b in 193 patients diagnosed with early invasive ductal carcinoma. Immunohistochemistry was performed to evaluate the expression of estrogen receptor (ER)‑α, progesterone receptor (PR) and human epidermal growth factor receptor‑2 (Her‑2). The positive expression rate of miR‑10b in patients with early invasive ductal carcinoma with ER‑α (+) or PR (+) was decreased compared with ER‑α (‑) or PR (‑) patients (P<0.05). Furthermore, the positive expression rate of miR‑10b in patients with Her‑2 (‑) was significantly increased compared with patients that were Her‑2 (+) (P=0.031). The positive expression rate of miR‑10b in the luminal B subtype was significantly decreased compared with that in the luminal A, Her‑2 and basal‑like subtypes (P=0.037). In patients that were identified as miR‑10b (+), the median disease‑free survival time was significantly increased in patients that were ER‑α (+)/PR (+)/Her‑2 (‑) compared with patients that were ER‑α (‑)/PR (‑)/Her‑2 (+) (P<0.05). In addition, the median disease‑free survival time was significantly decreased in Her‑2 overexpression and basal‑like subtypes when compared with luminal A and B subtypes (P<0.05). The molecular subtype was an independent prognostic factor for early invasive ductal carcinoma (odds ratios for luminal B, Basal‑like, and Her‑2 overexpression were 2.900, 5.232 and 4.214, respectively; all P<0.05). Positive expression of miR‑10b may also be a prognostic risk factor (odds ratio >1), though this was not statistically significant (P>0.05). The present findings indicated that miR‑10b‑positive expression was correlated with the expression of ER‑α, Her‑2 and the molecular subtypes of early invasive ductal carcinoma of the breast. [ABSTRACT FROM AUTHOR]